Mangoceuticals Statistics
Total Valuation
Mangoceuticals has a market cap or net worth of $6.71 million. The enterprise value is $6.76 million.
| Market Cap | 6.71M |
| Enterprise Value | 6.76M |
Important Dates
The last earnings date was Thursday, August 13, 2026, after market close.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Mangoceuticals has 17.17 million shares outstanding. The number of shares has increased by 208.69% in one year.
| Current Share Class | 17.17M |
| Shares Outstanding | 17.17M |
| Shares Change (YoY) | +208.69% |
| Shares Change (QoQ) | +3.87% |
| Owned by Insiders (%) | 16.15% |
| Owned by Institutions (%) | 7.07% |
| Float | 13.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 21.29 |
| Forward PS | n/a |
| PB Ratio | 0.56 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 21.45 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.18, with a Debt / Equity ratio of 0.02.
| Current Ratio | 0.18 |
| Quick Ratio | 0.16 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -37.14 |
Financial Efficiency
Return on equity (ROE) is -95.10% and return on invested capital (ROIC) is -51.39%.
| Return on Equity (ROE) | -95.10% |
| Return on Assets (ROA) | -47.95% |
| Return on Invested Capital (ROIC) | -51.39% |
| Return on Capital Employed (ROCE) | -105.16% |
| Weighted Average Cost of Capital (WACC) | 18.90% |
| Revenue Per Employee | $105,076 |
| Profits Per Employee | -$5.52M |
| Employee Count | 3 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.44% in the last 52 weeks. The beta is 2.03, so Mangoceuticals's price volatility has been higher than the market average.
| Beta (5Y) | 2.03 |
| 52-Week Price Change | -83.44% |
| 50-Day Moving Average | 0.44 |
| 200-Day Moving Average | 0.54 |
| Relative Strength Index (RSI) | 44.29 |
| Average Volume (20 Days) | 9,278,688 |
Short Selling Information
The latest short interest is 1.81 million, so 10.56% of the outstanding shares have been sold short.
| Short Interest | 1.81M |
| Short Previous Month | 1.88M |
| Short % of Shares Out | 10.56% |
| Short % of Float | 13.50% |
| Short Ratio (days to cover) | 0.05 |
Income Statement
In the last 12 months, Mangoceuticals had revenue of $315,227 and -$16.57 million in losses. Loss per share was -$1.12.
| Revenue | 315,227 |
| Gross Profit | 171,590 |
| Operating Income | -13.43M |
| Pretax Income | -15.10M |
| Net Income | -16.57M |
| EBITDA | -12.37M |
| EBIT | -13.43M |
| Loss Per Share | -$1.12 |
Balance Sheet
The company has $228,688 in cash and $279,207 in debt, with a net cash position of -$50,519 or -$0.00 per share.
| Cash & Cash Equivalents | 228,688 |
| Total Debt | 279,207 |
| Net Cash | -50,519 |
| Net Cash Per Share | -$0.00 |
| Equity (Book Value) | 12.52M |
| Book Value Per Share | 0.70 |
| Working Capital | -1.15M |
Cash Flow
| Operating Cash Flow | -3.89M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 1.06M |
| Net Borrowing | -86,556 |
| Free Cash Flow | -3.89M |
| FCF Per Share | -$0.23 |
Margins
| Gross Margin | 54.43% |
| Operating Margin | -4,261.46% |
| Pretax Margin | -4,791.54% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Mangoceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -208.69% |
| Shareholder Yield | -208.69% |
| Earnings Yield | -246.97% |
| FCF Yield | -57.98% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 16, 2024. It was a reverse split with a ratio of 1:15.
| Last Split Date | Oct 16, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |